Cemiplimab
Cemiplimab Basic information
- Product Name:
- Cemiplimab
- Synonyms:
-
- Cemiplimab
- Research Grade Cemiplimab(DHH02201)
- Cemiplimab (anti-PD-1)
- REGN-2810|||SAR-439684
- Research Grade Cemiplimab
- CAS:
- 1801342-60-8
- MW:
- 0
- Mol File:
- Mol File
Cemiplimab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Cemiplimab Usage And Synthesis
Uses
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research[1][2].
in vivo
Cemiplimab (i.p., 10 mg/kg, five injections within 2 weeks) can increased the proportion of effector T cells in tumors and dLNs to reduce tumor growth by combined immunotherapy with REGN3767 in MC38.Ova tumor mice model[2].
| Animal Model: | Female human PD-1×LAG-3 knockin mice (8-10 weeks) with MC38.Ova cells[2] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; five injections within 2 weeks |
| Result: | Partially inhibited the growth of MC38.Ova tumors and prolonged the survival of mice by administering alone. Significantly increased the proportion of CD4+ TILs in IFNγ and TNFα by combined immunotherapy with REGN3767. |
References
[1] Michael R Migden, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 Jul 26;379(4):341-351. DOI:10.1056/NEJMoa1805131
[2] Elena Burova, et al. Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice. Mol Cancer Ther. 2019 Nov;18(11):2051-2062. DOI:10.1158/1535-7163.MCT-18-1376
CemiplimabSupplier
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com